The purpose of this study was the development of personalized modes of therapy in elderly patients with isolated systolic hypertension (ISH). The study included 306 persons divided into two groups: Group 1(Control) included 150 elderly persons without arterial hypertension (AH), and Group 2 included 256 elderly patients (early old-age pension, between 65 and 74 years) with ISH (ESH/ESC,2013) according to the inclusion/exclusion criteria. All patients of Group 2 were divided into three subgroups depending on the combination of drugs at the beginning of the study. Group 2a (n=53) received amlodipine (5mg/day) and indapamide-retard (1.5 mg/day), Group 2b (n=53) received valsartan (80 mg/day) and indapamide-retard (1.5 vg/day), and Group2c (n=50) received amlodipine (5 mg/day) and valsartan (80 mg/day). The duration of therapy was 5.2 years. At the stage of data collection and screening, we applied standard methods for identification of ISH and secondary hypertension. Molecular phenotyping of blood serum was performed with methods of proteomics. We obtained the data of the molecular interactions and functional features of proteins from the STRING 10.0 database. Proteomic analysis contributes to the development of a personalized mode treatment in ISH patients, which is the safest and most efficient: 135 ISH patients switched to the administration of the amlodipine+valsartan combination.